Agalsidase Beta

證據等級: L5

預測適應症: 10 個

Agalsidase beta: From Fabry Disease to Cervical Neuroblastoma

One-Sentence Summary

Agalsidase beta (Fabrazyme) is a recombinant human enzyme replacement therapy (ERT) originally approved for Fabry disease, a rare lysosomal storage disorder caused by deficiency of α-galactosidase A. The TxGNN model predicts it may be effective for Cervical Neuroblastoma, ranking it as the top predicted new indication with a score of 98.37%. However, there are currently 0 clinical trials and 0 publications supporting this direction, and the mechanistic connection is considered extremely weak.

Quick Overview

Item	Content
Original Indication	Fabry disease (lysosomal storage disorder due to α-galactosidase A deficiency)
Predicted New Indication	Cervical Neuroblastoma
TxGNN Prediction Score	98.37%
Evidence Level	L5
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, Agalsidase beta is a recombinant form of human α-galactosidase A, the enzyme deficient in Fabry disease. It acts by replacing the missing enzyme, enabling the breakdown and clearance of GL-3 (globotriaosylceramide) glycosphingolipid, which otherwise accumulates pathologically in vascular endothelium, kidneys, heart, and nervous system.

The predicted new indication — cervical neuroblastoma — is a neural crest-derived malignant tumour. There is a theoretical hypothesis that glycosphingolipid metabolism dysregulation may influence the tumour microenvironment and apoptotic pathways in neural crest tumours. However, no direct mechanistic research links α-galactosidase A activity to neuroblastoma biology, and the connection between GL-3 clearance and tumour suppression in this context is entirely speculative.

Importantly, the top 10 predictions are all head, neck, or skull-base neoplasms with near-identical scores (ranging from 0.9837 to 0.9828), a pattern strongly indicative of graph topology bias rather than true biological signal. This clustering suggests TxGNN has connected Agalsidase beta to these tumours via shared "neurological disease" or "neoplasm" intermediate nodes in the knowledge graph, rather than through a direct pharmacological relationship. This further weakens confidence in the predicted indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Agalsidase beta is currently not registered in Singapore. No marketing authorizations or product licences are on file.

Note: Agalsidase beta (brand name Fabrazyme) is approved in the EU, USA, and other jurisdictions for Fabry disease treatment. A regulatory filing pathway would need to be established before any clinical use in Singapore.

Safety Considerations

Please refer to the package insert for safety information.

Note: All safety fields (key warnings, contraindications, drug interactions) were not available in the current Evidence Pack. Full safety data should be retrieved from the Fabrazyme package insert (FDA/EMA) before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 predicted indications are classified at evidence level L5 (model prediction only, no supporting studies), and the top prediction — cervical neuroblastoma — has no clinical trials, no publications, and a mechanistic link assessed as extremely weak. The near-identical prediction scores across all 10 head-and-neck tumours strongly suggest graph topology artefacts rather than genuine repurposing opportunities. Proceeding under these conditions would not be scientifically justifiable.

To proceed, the following is needed:

Mechanistic validation: Obtain full MOA data from DrugBank API (DB00103) to confirm whether any biological pathway plausibly connects GL-3 clearance to neuroblastoma or other predicted tumours
Safety data retrieval: Download and parse the Fabrazyme package insert (FDA/EMA) to populate key warnings, contraindications, and special population data
Literature deep-dive: Conduct a broader PubMed search on "Agalsidase beta" + "cancer" / "tumour" / "neoplasm" to confirm absence of any preclinical signal
Graph artefact investigation: Review why TxGNN clusters Agalsidase beta with head-and-neck neoplasms; consider excluding predictions where ≥5 structurally similar diseases share near-identical scores
Re-ranking consideration: Evaluate whether lower-ranked predictions (not shown in this pack) may offer more mechanistically plausible repurposing candidates — for example, conditions involving vascular, renal, or cardiac pathology where GL-3 accumulation has documented relevance
Singapore regulatory pathway: If a viable indication is identified in the future, note that HSA registration would require a full NDA/MAA submission, as the product has no current Singapore market presence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.